NL-OMON56042招募中不适用
Safely reduce cystoscopic evaluations for microscopic Hematuria patients (SeARCH Trial). - SeARCH Trial
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •In order to be eligible to participate in this study a written informed consent
- •is required. Thereby, a subject must meet the following criteria based on the
- •most recent American Urological Association guideline on microscopic hematuria
- •- Microscopically confirmed microscopic hematuria of voided urine defined as >=3
- •erythrocytes per high power field
- •- Male patients >=40 years
- •- Female patients >=50 years
排除标准
- •- History of urothelial bladder- or urinary tract cancer
- •- Presence of macroscopic (visible) hematuria
- •- Woman who is or may be pregnant
研究者
相似试验
已完成
1 期
ELIMINATION OF CYSTICERCOSIS IN PER-B68 Taeniasis-B690 Cysticercosis of central nervous systemCysticercosis of central nervous systemB68B690TaeniasisPER-002-05BILL & MELINDA GATES FOUNDATION,103,554
进行中（未招募）
1 期
A Phase 3 trial of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible participants with MIBCMuscle-invasive Bladder Cancer (MIBC)MedDRA version: 21.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 100000004864EUCTR2018-003809-26-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.836
进行中（未招募）
1 期
A Phase 3 trial of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with MIBCMuscle-invasive Bladder Cancer (MIBC)MedDRA version: 21.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 100000004864EUCTR2018-003809-26-BEMerck Sharp & Dohme LLC608
进行中（未招募）
1 期
A Phase 3 trial of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible participants with MIBCMuscle-invasive Bladder Cancer (MIBC)MedDRA version: 21.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 100000004864EUCTR2018-003809-26-DKMerck Sharp & Dohme LLC608
进行中（未招募）
1 期
A Phase 3 trial of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible participants with MIBCMuscle-invasive Bladder Cancer (MIBC)MedDRA version: 21.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 100000004864EUCTR2018-003809-26-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.836